AI Co. Funded To Develop AI Approach to Health Equity

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS) announced that it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. 

This is in partnership with Minneapolis' Rush River Research, as the companies work together to create AI that will be culturally appropriate when engaging with African American families. 

According to the press release, "Current methods used by clinicians to collect family medical histories often do not satisfactorily capture important information from blended families or non-traditional relationships commonly found in racial or ethnic minority communities."

Dr. Kevin Peterson, the chief medical officer of Treatment.com AI, stated, "Old data approaches inevitably reflect old biases. Treatment confronts issues of historical bias by reinventing how data about families is collected and stored to reflect the realities of modern life."

Treatment.com AI noted that there is systematic bias and a history of trauma prevalent among African American communities in terms of healthcare. This can limit treatment as it may create information gaps about the health in patients' relatives. With this in mind, Treatment.com is utilizing its AI to disrupt how family health is collected and recorded to "address existing disparities." The company has sought to address these issues through focus groups with African American doctors and community members. 

Building on their partnership, Rush River Research and Treatment.com AI have submitted an expanded Phase 2 grant proposal to the NIH, which will allow them to further expand their work. The aim is to shift this from a prototype into a commercial solution, with the goal of adoption and integration with standard electronic health records and online apps.

Implicit Bias in Medical Spaces

Treatment and Rush River are not the only ones who see this need to combat implicit bias in medical spaces.

According to a 2015 review by AM J Public Health, Most healthcare providers appear to have an implicit bias in terms of positive attitudes toward Whites and negative attitudes toward people of color." While the study reported that future studies are necessary to examine these relationships more closely, "Interventions targeting implicit attitudes among health care professionals are needed because implicit bias may contribute to health disparities for people of color."

A 2016 study published by Princeton University found that of 418 medical students, half endorsed incorrect beliefs about Black patients, including the false narrative that "their skin is thicker than white people's" and that their pain tolerance is higher.

This can lead to a lot of Black patients not being properly treated and increases the wariness of medical professionals in non-white communities. 

Market Estimated To reach US$148.4 Billion

Not only is there a need (as shown above) for culturally sensitive medical services, but the market for AI healthcare services and software is massive. 

Markets and Markets recently reported that the international AI healthcare market is valued at US$20.9 billion and estimated to reach us$148.4 billion by 2029, "registering a CAGR of 48.1%."

The growth will be facilitated by the expanding need to reduce costs in the healthcare sector, as well as the increased patient need. And AI is only getting more popular in the healthcare space.

According to reporting from Statista "In 2021, the artificial intelligence (AI) in healthcare market was worth around US$11 billion worldwide. It was forecast that the global healthcare AI market would be worth almost US$188 billion by 2030."

Treatment.com AI is ready to rise to that increased demand. As Technical Analyst Clive Maund wrote in a February posting, the company "should have a very bright future." Maund went on to reiterate that "the growth potential of this industry is enormous."

Maund went on to analyze Treatment's charts and found that not only was the growth potential there, but "with a breakout from the base pattern looking increasingly likely soon, the stock is rated a Strong Buy for all timeframes, and the upside potential from the current historically low level is very substantial, especially in percentage terms."

Additional Products on the Way

While specifics have not yet been released, Treatment.com AI has said it plans to release additional projects in the healthcare space in 2024. 

The company reported that any of these additional products could factor into a boost in their stock. 

Ownership and Share Structure

According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of Treatment.com AI. They are Chief Medical Officer, Chairman and Director Dr. Kevin Peterson with 10.35% or 3.84M shares and John Fraser with 2.76% or 1.03M shares.

Retail investors own the remaining 86.88%. There are no institutional investors currently.

The company has 37.11M outstanding shares and 32.24M free float traded shares.

Its market cap is CA$17.33 million, and its 52-week trading range is CA$0.10−1.20 per share.

Important Disclosures:

1. Treatment.com AI Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc.
3. Katherine DeGilio wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Contributing Author Disclosures:

1. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing this article. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in this content accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed.

Clivemaund.com Disclosures

The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor.